{
    "organizations": [],
    "uuid": "4a8611c38293ca9d08254990141404f5a2a1963d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-athenex-receives-positive-feedback/brief-athenex-receives-positive-feedback-from-fda-on-the-design-of-phase-iii-clinical-trial-for-oraxol-idUSASB0C114",
    "ord_in_thread": 0,
    "title": "BRIEF-Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - Athenex Inc:\n* ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL\n* ATHENEX INC - SECOND INTERIM ANALYSIS OF ORAXOL PHASE III CLINICAL STUDY BASED ON 180 EVALUABLE PATIENTS IS PLANNED FOR MIDDLE OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-16T21:10:00.000+02:00",
    "crawled": "2018-01-17T20:06:50.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "athenex",
        "inc",
        "athenex",
        "receives",
        "positive",
        "feedback",
        "fda",
        "design",
        "phase",
        "iii",
        "clinical",
        "trial",
        "oraxol",
        "athenex",
        "inc",
        "second",
        "interim",
        "analysis",
        "oraxol",
        "phase",
        "iii",
        "clinical",
        "study",
        "based",
        "evaluable",
        "patient",
        "planned",
        "middle",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}